Objective appetite assessment measures, such as appetite peptides (serum ghrelin, peptide YY, leptin), are considered predictors of cancer progression and metastasis, influencing disease outcomes, survival and malnutrition [21,22]; nevertheless, ghrelin concentrations are rarely evaluated in everyday clinical practice. This evidence concerns the gene GHRL and cancer.